Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy

doi:10.3748/wjg.v28.i42.6034

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 42

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5184)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

269

WORD

HTML

2611

Figures (1-1)

283

Tables (1-2)

201

Sum=3407

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

145

Download

448

Sum=593

Publishing Process of This Article

Item

Count

Browse

315

Download

869

Sum=1184

Nov 14, 2022 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Nov 14, 2022; 28(42): 6034-6044
Published online Nov 14, 2022. doi: 10.3748/wjg.v28.i42.6034

Table 2 Phase III clinical trials of combinations of anti-angiogenic inhibitors and immune checkpoint inhibitors in hepatocellular carcinoma

Trial name	Treatment	Setting	Primary endpoints	Current status	Enrollment, n
NCT03434379	Atezolizumab + bevacizumab	Advanced HCC; first line	OS, PFS	Active, not recruiting	558
NCT04770896	Atezolizumab + lenvatinib/sorafenib versus lenvatinib/sorafenib	Unresectable HCC; second line	OS	Recruiting	554
NCT03713593	Pembrolizumab + lenvatinib versus lenvatinib	Advanced HCC; first line	OS, PFS	Active, not recruiting	794
NCT03755791	Atezolizumab + cabozantinib versus sorafenib	Advanced HCC; first line	OS, PFS	Recruiting	740

OS: Overall survival; PFS: Progression free survival; HCC: Hepatocellular carcinoma.

Citation: Li SQ, Yang Y, Ye LS. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol 2022; 28(42): 6034-6044
URL: https://www.wjgnet.com/1007-9327/full/v28/i42/6034.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i42.6034